X2 Biosystems has signed a contract to support the US Army Aeromedical Research Laboratory’s (USAARL) testing of its concussion and traumatic brain injury (TBI) detection and management system.
The contract was awarded by the US Army Medical Research and Materiel Command (USAMRMC) through the rapid innovation fund (RIF) programme, and will be executed in collaboration with Trifecta Solutions.
It will allow USAARL to evaluate the system for field readiness and potential inclusion in several garrison training environments.
X2 Biosystems Government and Industrial Division president US Army retired major general Steve Layfield said: "There is no more important work than assuring that our servicemen and women benefit from medical advances that can make a crucial difference in health outcomes, wherever our military forces are called to serve.
"Because X2 Biosystems’ advanced technology is the gold standard in concussion and TBI management technology, we are confident our technology will allow the army to meet its goals in addressing TBI."
X2 Biosystems chief executive officer John Ralston said: "X2 Biosystems’ proven, mature technology meets the army’s need for rapid transition of proven, commercial off-the-shelf technology for military application."
The company’s integrated concussion management is designed to help medical teams more effectively monitor impact events, promote adherence to standards of care and coordinate a return to activity. It also contributes to the understanding of both acute and long-term brain health outcomes.
The system creates a durable medical record and adds a level of objective precision for the assessment of concussive events and other traumatic brain injuries with simplicity and ease-of-use.
Addressing TBI continues to be a significant issue for US military forces.
The army requires combat medics to accurately and objectively assess soldiers with mild to moderate TBI up to 24 hours after the injury, and improve diagnosis, treatment, rehabilitation and return to duty.